Glaukos Corp (GKOS)vsStryker Corporation (SYK)
GKOS
Glaukos Corp
$224.41
+2.01%
HEALTHCARE · Cap: $10.69B
SYK
Stryker Corporation
$335.08
-2.75%
HEALTHCARE · Cap: $111.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 4192% more annual revenue ($26.30B vs $612.84M). SYK leads profitability with a 13.8% profit margin vs -30.7%. SYK appears more attractively valued with a PEG of 1.37. SYK earns a higher WallStSmart Score of 57/100 (C).
GKOS
Hold45
out of 100
Grade: D+
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.6%
Fair Value
$119.31
Current Price
$224.41
$105.10 discount
Margin of Safety
-23.8%
Fair Value
$235.79
Current Price
$335.08
$99.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 49.5% year-over-year
Earnings expanding 1896.0% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Strong operational efficiency at 20.3%
Generating 1.1B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 19.3x book value
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 49.5% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.37 suggests the stock is reasonably priced for its growth.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
GKOS profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.78 — expect wider price swings.
GKOS is growing revenue faster at 49.5% — sustainability is the question.
SYK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (57/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?